Frequency Distribution of CYP2C9 and VKORC1 Mutations among Bulgarian Patients and their Importance for Anticoagulant Therapy

被引:0
|
作者
Velizarova, Milena [1 ,2 ]
Abedinov, Philip [3 ]
Svinarov, Dobrin [1 ,2 ]
Nikolov, Valentin [4 ]
Hristova, Julieta [1 ,2 ]
机构
[1] Med Univ Sofia, Fac Med, Dept Clin Lab, Sofia, Bulgaria
[2] Alexander Univ Hosp, Sofia, Bulgaria
[3] St Ekaterina Univ Hosp, Sofia, Bulgaria
[4] SGP Bio Dynam Ltd, Sofia, Bulgaria
关键词
CYP2C9; oral anticoagulants; pharmacogenetics; VKORC1; GENETIC POLYMORPHISMS; PRESCRIBING ERRORS; WARFARIN; PREVALENCE; REQUIREMENT; GENOTYPE;
D O I
10.7754/Clin.Lab.2022.220213
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Genetic polymorphisms of CYP2C9 and VKORC1 play a major role in pharmacokinetics and pharmacodynamics of coumarin anticoagulants. The purpose of our study was to assess the relative frequency of the above mutations in Bulgarian population in order to predict bleeding tendencies and precisely manage the anticoagulant therapy during the postoperative period after cardiac surgery with extracorporeal circulation. Methods: Genomic DNA samples from 200 Bulgarian patients subjected to cardiac surgery with extracorporeal circulation were analyzed for VKORC1 1639G>A and CYP2C9*2&*3 polymorphisms by real-time polymerase chain reaction (PCR), then allele frequencies of various genotypes were calculated by Hardy-Weinberg Equilibrium. Results: Median patients' age was 63.9 +/- 10.8 years; 66.5% were male. Median BMI was 28.6 +/- 5.4 kg/m 2 . Genotype distribution for CYP2C9 was *1/*1 - 51%, *1/*2 - 21%, *1/*3 - 13.5%, *2/*3 - 4%, *3/*3 - 2%, and *2/*2 1.5%. The calculated frequency of CYP2C9*1 allele was 74.25%, CYP2C9*2 allele was 13%, and CYP2C9*3 allele was 12.75%, and all allelic frequencies were in Hardy-Weinberg equilibrium (p-value = 0.358). The major VKORC1 genotype was G/A - 47%, followed by G/G - 35.5% and A/A - 17.5%). Based on Hardy-Weinberg Equilibrium, there was no significant difference between observed and expected frequencies (X - -3.779), presumably as a result of the homogeneity in the population. Conclusions: Analysis of the data obtained in the course of the study suggested that identification of homozygous carriers of VKORC1-1639 G>A (rs9923231) in Bulgarians may be useful in developing recommendations for personalized therapy. On the contrary, homozygous carriers of CYP2C9*2 or *3, included only 4.5% of the studied patients, thus indicating that this group would benefit less from dosing algorithms. Our results demonstrated good agreement with the results obtained in other studies conducted in the Caucasian population.
引用
收藏
页码:2527 / 2532
页数:6
相关论文
共 50 条
  • [1] VKORC1 and CYP2C9 genotype distribution in Asian countries
    Gaikwad, Tejasvita
    Ghosh, Kanjaksha
    Shetty, Shrimati
    THROMBOSIS RESEARCH, 2014, 134 (03) : 537 - 544
  • [2] Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients
    Oscanoa, Teodoro J.
    Guevara-Fujita, Maria L.
    Fujita, Ricardo M.
    Munoz-Paredes, Maria Y.
    Acosta, Oscar
    Romero-Ortuno, Roman
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (03) : 769 - 775
  • [3] Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups
    Scott, Stuart A.
    Khasawneh, Rame
    Peter, Inga
    Kornreich, Ruth
    Desnick, Robert J.
    PHARMACOGENOMICS, 2010, 11 (06) : 781 - 791
  • [4] POLYMORPHISMS OF GENES CYP2C9 AND VKORC1 IN PATIENTS WITH VENOUS THROMBOEMBOLIC COMPLICATIONS IN MOSCOW POPULATION: EFFECTS ON STABILITY OF ANTICOAGULANT THERAPY AND FREQUENCY OF HEMORRHAGE
    Vorobyeva, N. M.
    Panchenko, E. P.
    Dobrovolsky, A. B.
    Titaeva, E. V.
    Khasanova, Z. B.
    Konovalova, N. V.
    Postnov, A. Yu.
    Kirienko, A. I.
    TERAPEVTICHESKII ARKHIV, 2011, 83 (06) : 59 - 65
  • [5] The Frequency of CYP2C9, VKORC1, and CYP4F2 Polymorphisms in Russian Patients With High Thrombotic Risk
    Ivashchenko, Dmitriy
    Rusin, Ilya
    Sychev, Dmitriy
    Grachev, Audrey
    MEDICINA-LITHUANIA, 2013, 49 (12): : 517 - 521
  • [6] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    Ozgon, G. Oner
    Langaee, T. Y.
    Feng, H.
    Buyru, N.
    Ulutin, T.
    Hatemi, A. C.
    Siva, A.
    Saip, S.
    Johnson, J. A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (09) : 889 - 894
  • [7] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    G. Oner Ozgon
    T. Y. Langaee
    H. Feng
    N. Buyru
    T. Ulutin
    A. C. Hatemi
    A. Siva
    S. Saip
    J. A. Johnson
    European Journal of Clinical Pharmacology, 2008, 64 : 889 - 894
  • [8] Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users
    Verhoef, T. I.
    Redekop, W. K.
    Buikema, M. M.
    Schalekamp, T.
    van der Meer, F. J. M.
    Le Cessie, S.
    Wessels, J. A. M.
    van Schie, R. M. F.
    De Boer, A.
    Teichert, M.
    Visser, L. E.
    Maitland-van der Zee, A. H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (04) : 606 - 614
  • [9] Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
    Flockhart, David A.
    O'Kane, Dennis
    Williams, Marc S.
    Watson, Michael S.
    Flockhart, David A.
    Gage, Brian
    Gandolfi, Roy
    King, Richard
    Lyon, Elaine
    Nussbaum, Robert
    O'Kane, Dennis
    Schulman, Kevin
    Veenstra, David
    Williams, Marc S.
    Watson, Michael S.
    GENETICS IN MEDICINE, 2008, 10 (02) : 139 - 150
  • [10] VKORC1 and CYP2C9 Genes Polymorphisms, Affecting the Sensitivity of Anticoagulant Therapy in Patients with Acute Cerebral Circulation Impairment
    Chugunova, S. A.
    Nikolaeva, T. Ja.
    Danilova, A. N.
    Kurtanov, H. A.
    Maksimova, N. R.
    Sofronova, S. I.
    YAKUT MEDICAL JOURNAL, 2014, (02): : 159 - 166